Pharmacological rationale for antihypertensive drug choice on COVID-19-affected patients: ACEI/ARB might not increase their susceptibility

J Cell Mol Med. 2020 Nov;24(21):12879-12881. doi: 10.1111/jcmm.15850. Epub 2020 Sep 17.

Authors

Hong-Jin Zhao¹, Xiao-Mei Yang², Ai-Hong Wang¹, Yan Li³

Affiliations

¹ Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
² Department of Anesthesiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, China.
³ School of Medicine, Cheeloo College of Medicine, Shandong University, Ji'nan, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / pharmacology
Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme 2 / genetics
Angiotensin-Converting Enzyme 2 / metabolism*
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Animals
Antihypertensive Agents / pharmacology
Antihypertensive Agents / therapeutic use*
COVID-19 / metabolism
COVID-19 Drug Treatment*
Comorbidity
Female
Humans
Hypertension / drug therapy
Hypertension / epidemiology
Premenopause

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
ACE2 protein, human
Angiotensin-Converting Enzyme 2

Grants and funding